Ghassan Abou-Alfa, MD

Articles by Ghassan Abou-Alfa, MD
PROOF 301: Infigratinib Versus Gemcitabine Plus Cisplatin for CCA With FGFR2 Rearrangements
Ghassan Abou-Alfa, MDBile Duct Cancer | March 13, 2025
Dr. Abou-Alfa describes the promising outcomes of infigratinib and delves into further research on FGFR alterations in CCA.
View More

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    Contact Us

    eNewsletters

    Contribute

    Career Center

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |